VALIDATE-BSI 2019 Conference Programme

The Drum at Wembley

Wednesday 2 October 2019 (afternoon and evening)


1200   Registration and buffet lunch for all delegates

1300   Welcome

Helen McShane

1300   Prof Helen McShane

  VALIDATE Director, University of Oxford, UK

  Welcome to conference & introduction to VALIDATE


Doug Brown

1310   Dr Doug Brown

  Chief Executive, British Society for Immunology (BSI), UK

  BSI Welcome address


1320   Session 1: Tissue-specific immunity, host-pathogen interactions, macrophages and the microenvironment - Chair Prof Andrea Cooper, University of Leicester

Clare Lloyd

 1320   Keynote Speaker: Prof Clare Lloyd

   Imperial College London, UK

            Local and environmental cues dictate the nature of the pulmonary immune response (abstract)


Barbara Kronsteiner-Dobramysl

  1400   Dr Barbara Kronsteiner-Dobramysl

    University of Oxford, UK

             Diabetes alters cellular metabolism of T cells: implications for vaccine development (abstract)


Chidchamai Kewcharoenwong

1420   Dr Chidchamai Kewcharoenwong

  Khon Kaen University, Thailand

           Glibenclamide alters cytokine production of primary human monocytes from diabetic individuals against Mycobacterium tuberculosis infection (abstract)


Isadora Lima

1440   Dr Isadora Lima

  FIOCRUZ, Brazil

           Canine visceral leishmaniasis: the role of tissue-specific immunity in the progression of disease (abstract)


1500   Tea/coffee break

Tracy Hussell

1530   Keynote Speaker: Prof Tracy Hussell

  University of Manchester, UK

  Innate sensing of lung health and disease (abstract)


Lisa Stockdale

1610   Dr Lisa Stockdale

  University of Oxford, UK

  Cytomegalovirus as a correlate of risk for TB? (abstract)


1630   Poster turbo talks:

1630  Asst Prof Kiran Afshan, Quaid-i-Azam University, Pakistan

 Cutaneous Leishmaniasis in Khyber Pakhtunkhwa, Pakistan (abstract)

1634  Dr Anthony Afum-Adjei Awuah, Kumasi Centre for Collaborative Research (KCCR), Ghana

 Why fix when you can prevent; towards TB Vaccines Research in Ghana (abstract)

1638  Dr Federico Carlos Blanco, National Institute of Agricultural Technology (INTA), Argentina

The isolate Mb04-303 induce a proinflammatory innate immune profile and is a potential candidate for an attenuated mutant vaccine against bovine tuberculosis (abstract)

1642  Assoc Prof Mary Burtnick, University of Nevada, Reno, USA

Optimization of melioidosis subunit vaccines using Burkholderia thailandensis E555 (abstract)

1646  Dr Panjaporn Chaichana, MORU, Thailand

Identification of protective antibody profiles for vaccine development against melioidosis (abstract)

1650  Assoc Prof Narisara Chantratita, Mahidol University, Thailand

Risk of Burkholderia pseudomallei infection, host immune response and biomarkers for melioidosis (abstract)

1654  Asst Prof Ganjana Lertmemongkolchai, Khon Kaen University, Thailand

Metformin-induced suppression of IFN-α expression via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in diabetes mellitus (abstract)

1658  Dr Rachel Okojie, University of Benin, Nigeria

Comparative study of the immunological and haematological parameters among tuberculosis naive and treated patients in Central Hospital, Benin City, Nigeria (abstract)

1702  Dr Olayinka Osuolale, Elizade University, Nigeria

Leishmaniasis in patients attending a medical health center in the rural community of Ilara-Mokin, Ondo State, Nigeria (abstract)

1706  Asst Prof Vijay Kumar Prajapati, Central University of Rajasthan, India

 Evaluation of immunogenicity of the engineered multi-epitope subunit vaccine against visceral leishmaniasis infection (abstract)

1710  Dr Lok Bahadur Shrestha, BP Koirala Institute of Health Sciences, Nepal

 Emerging Clinical Microbiologist looking for research opportunity in TB Vaccinology (abstract)

1714  Dr Suwarti, Eijkman Oxford Clinical Research Unit (EOCRU), Indonesia

 Intranasal boosting regimen of Human Parainfluenza Virus Type 2-Ag85B vaccines induces superior CD4 immune response against Mycobacterium tuberculosis (abstract)

1718 Dr Julen Tomás Cortázar, University College Dublin, Ireland

Elucidating the mechanisms of protection of the Burkholderia pseudomallei antigen, BpOmpW (abstract)

1722  Chathika Weersuriya, LSHTM, UK

 Mathematical modelling of the epidemiological impact, cost-effectiveness and budget impact of novel tuberculosis vaccines on multi-drug resistant tuberculosis (abstract)

1730   Group photograph

  Drinks reception with poster session (abstracts)

1900   Conference Dinner


Thursday 3 October 2019 (full day)


0830   Coffee/tea

0900   Session 2: Biomarkers - Chair Prof Helen Fletcher, LSHTM


0900   Keynote Speaker: Dr January Weiner

   Berlin Institute of Health, Germany

            Biomarkers in tuberculosis and individual variability of the host (abstract)


Fatoumatta Darboe

0940   Dr Fatoumatta Darboe

  MRC Unit at LSHTM, The Gambia

  Predicting and diagnosing TB disease in HIV-infected persons (abstract)


Eduardo Milton Ramos Sanchez

1000   Dr Eduardo Milton Ramos Sanchez

  University of São Paulo, Brazil

  Altered expression of microRNAs in infections with cutaneous and visceral strains of Leishmania (abstract)


1020   Tea/coffee break

Stephen Gordon

1050   Keynote Speaker: Prof Stephen Gordon

   University College Dublin, Ireland

            One Health route to exploring virulence in the Mycobacterium tuberculosis complex (abstract)


Hannah Painter

1130   Hannah Painter


  Development of an ex vivo mycobacterial growth inhibition assay using murine lung cells for tuberculosis vaccine testing (abstract)


Tufária Mussá

1150   Asst Prof Tufária Mussá

  Eduardo Mondlane University, Mozambique

  The fusion protein Ag85B-Acr-HBHA (FP1) elicits IFN-γ, IL-2 and TNF-α in conventional T cells of Tuberculosis contacts with latent infection over time (abstract)


1210   Lunch

1310   Session 3: Latest vaccine developments - Chair Prof Helen McShane, University of Oxford

Paul Brett

1310   Keynote Speaker: Assoc Prof Paul Brett

  University of Nevada, Reno, USA

  Development of multivalent subunit vaccines for immunization against melioidosis (abstract)


Sophie Rhodes

1350   Dr Sophie Rhodes


  Dose finding for new vaccines: the role for immunostimulation/immunodynamic modelling (abstract)


Deepa Paliwal

1410   Dr Deepa Paliwal

  University of Reading, UK

  Progress in a reverse vaccinology approach for bovine TB (abstract)


1430   Tea/coffee break

Mark Hatherill

1500   Keynote Speaker: Prof Mark Hatherill

  University of Cape Town, South Africa

  Major Advances and Next Steps for Tuberculosis Vaccine Development (abstract)


Justice Boakye-Appiah

1540   Dr Justice Boakye-Appiah

  St George's University of London, UK

  Mycolactone based vaccine against Buruli ulcer disease (abstract)


Rebecca Harris

1600   Asst Prof Rebecca Harris


  Potential impact of new tuberculosis vaccines in China, South Africa and India and implications for vaccine development (abstract)


Helen McShane

1620   Prof Helen McShane

  VALIDATE Director, University of Oxford, UK

  Wrap up and conference close


1630   Conference ends


To register for the VALIDATE-BSI 2019 Conference, visit our Conference and Annual Meeting webpage. Registration closes 6th September.


Printable version of the Programme: